Novartis’s Triple Clinical Setback Hits Shares and Weighs on Pharma Peers on September 11, 2026 Amgen Avidity Biosciences del-desiran eli lilly Novartis Pelacarsen pharmaceutical sector Phase 3 Clinical Trials rap-cel +